Scarica l'app Stockscreener
2.5604
2.18%
0.0404
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.52
Aprire:
$2.52
Volume 24 ore:
210.86K
Relative Volume:
0.64
Capitalizzazione di mercato:
$168.59M
Reddito:
-
Utile/perdita netta:
$-30.84M
Rapporto P/E:
-5.2803
EPS:
-0.4849
Flusso di cassa netto:
$-23.88M
1 W Prestazione:
+18.66%
1M Prestazione:
+5.10%
6M Prestazione:
-51.87%
1 anno Prestazione:
+101.16%
Intervallo 1D:
$2.4855
$2.6299
Intervallo di 1 settimana:
$2.07
$2.6299
Portata 52W:
$1.22
$7.13
Galectin Therapeutics Inc Stock (GALT) Company Profile
Nome
Galectin Therapeutics Inc
Settore
Industria
Telefono
678-620-3186
Indirizzo
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Compare GALT vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GALT
Galectin Therapeutics Inc
|
2.56 | 165.96M | 0 | -30.84M | -23.88M | -0.4849 |
VRTX
Vertex Pharmaceuticals Inc
|
433.86 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
635.28 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
811.63 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.12 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-17 | Ripresa | H.C. Wainwright | Buy |
| 2020-08-13 | Reiterato | H.C. Wainwright | Buy |
| 2019-02-13 | Iniziato | B. Riley FBR | Buy |
| 2017-12-07 | Reiterato | H.C. Wainwright | Buy |
| 2017-11-28 | Reiterato | H.C. Wainwright | Buy |
| 2017-10-19 | Iniziato | ROTH Capital | Buy |
| 2017-03-30 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2016-10-03 | Downgrade | FBR & Co. | Outperform → Mkt Perform |
| 2016-09-29 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2016-09-28 | Downgrade | ROTH Capital | Buy → Sell |
| 2016-03-28 | Ripresa | H.C. Wainwright | Buy |
| 2015-09-21 | Iniziato | H.C. Wainwright | Buy |
| 2014-08-01 | Downgrade | Aegis Capital | Buy → Hold |
| 2014-07-30 | Reiterato | MLV & Co | Buy |
| 2014-07-29 | Reiterato | MLV & Co | Buy |
| 2014-04-02 | Reiterato | MLV & Co | Buy |
| 2014-02-10 | Reiterato | Aegis Capital | Buy |
| 2014-01-09 | Reiterato | Aegis Capital | Buy |
| 2013-12-03 | Iniziato | MLV & Co | Buy |
| 2013-08-19 | Reiterato | Aegis Capital | Buy |
Mostra tutto
Galectin Therapeutics Inc Borsa (GALT) Ultime notizie
Number of shareholders of Galectin Therapeutics Inc. – NASDAQ:GALT - TradingView
TradingKey - TradingKey
Galectin Therapeutics 1Q Research and Development Expenses $2.2M >GALT - Moomoo
Galectin Therapeutics Q1 2026 Financial Report: Earnings, Balance Sheet, and Key Disclosures - Minichart
Galectin Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Is Galectin Therapeutics (GALT) Fairly Valued After Q1 2026 Earn - GuruFocus
Correct: Galectin Therapeutics 1Q Loss/Shr 8c >GALT - Moomoo
Galectin Therapeutics Reports Q1 2026 Financial Results and Advances Belapectin for MASH Cirrhosis with Positive NAVIGATE Trial Data 123 - Minichart
Galectin Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update - The Manila Times
Belapectin reduces liver stiffness in high-risk MASH cirrhosis trial - Stock Titan
Galectin Therapeutics reports Q1 2026 net loss of $5.1M, cash $14.1M; updates belapectin program - TradingView
Galectin Therapeutics 1Q 2026: Financials Not Reported — 10-Q Summary - TradingView
Galectin Therapeutics (NASDAQ: GALT) trims Q1 2026 loss as R&D falls - Stock Titan
Galectin Therapeutics (NASDAQ: GALT) narrows Q1 2026 loss but leans on large convertible debt - Stock Titan
Galectin Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Will Galectin's New MASH Cirrhosis Data Renew Stock Momentum? - RTTNews
Galectin Therapeutics (GALT) Highlights Promising Phase 2b Trial Results - GuruFocus
Galectin Therapeutics Inc expected to post a loss of 6 cents a shareEarnings Preview - TradingView
Galectin Therapeutics announces publication of Navigate phase 2b trial results for belapectin in the Journal of Hepatology - marketscreener.com
Galectin publishes phase 2b trial results in Hepatology - Investing.com
Galectin Therapeutics Announces Publication Of Navigate Phase 2B Trial Results For Belapectin In The Journal Of Hepatology - TradingView
Galectin publishes phase 2b trial results in Hepatology By Investing.com - Investing.com Australia
Galectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatology - Yahoo Finance
Why Galectin Therapeutics (GALT) guidance matters more than actual results | Q4 2025: Better Than ExpectedBuy Rating - newser.com
Galectin Therapeutics to Present New Data on the Treatment of Fatty Liver Disease and Fibrosis at AA - Yahoo
GALT Stock Price, Quote & Chart | GALECTIN THERAPEUTICS INC (NASDAQ:GALT) - ChartMill
Galectin Therapeutics, Inc. Investigated by the Portnoy Law Firm - GlobeNewswire
Galectin Therapeutics (GALT) upgraded to buy: What does it mean for the stock? - MSN
GALT Price Today: Galectin Therapeutics Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
What are the key catalysts for Galectin Therapeutics (GALT) stock (Drifts Higher) 2026-04-23Post Earnings - newser.com
GALT (Galectin Therapeutics Inc.) Q4 2025 narrower than expected loss drives 8.41 percent share gain amid positive investor sentiment.Earnings Per Share - UBND thành phố Hải Phòng
GALT (Galectin Therapeutics Inc.) posts narrower Q4 2025 loss than estimates, shares gain 3.64 percent on upbeat investor reaction.Expert Momentum Signals - UBND thành phố Hải Phòng
Is institutional money buying Galectin Therapeutics (GALT) stock (Smart Money Exits) 2026-04-20Open Stock Signal Network - UBND thành phố Hải Phòng
Buy Signal: What is the long term forecast for Galectin Therapeutics Inc stockTrade Analysis Report & Consistent Profit Trading Strategies - baoquankhu1.vn
[EFFECT] GALECTIN THERAPEUTICS INC SEC Filing - Stock Titan
Targets Report: Whats next for Galectin Therapeutics Inc stockBond Market & Weekly Setup with High ROI Potential - baoquankhu1.vn
Dip Buying: Can Galectin Therapeutics Inc weather a recession2026 Major Catalysts & Weekly Stock Performance Updates - baoquankhu1.vn
Is Galectin Therapeutics (GALT) Stock Reacting to Market | Price at $2.37, Up 6.76%Retail Trader Ideas - newser.com
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Earnings Risk: Is Galectin Therapeutics Inc stock a buy or sell2026 Key Highlights & Smart Swing Trading Techniques - baoquankhu1.vn
Trend Recap: What is the long term forecast for Galectin Therapeutics Inc stock2026 Summary & Consistent Return Investment Signals - baoquankhu1.vn
Is Galectin Therapeutics (GALT) Stock Worth Holding | Price at $2.61, Down 2.25%Expert Momentum Signals - newser.com
Galectin Therapeutics (GALT) Eps Diluted (TTM) - Zacks Investment Research
Galectin Therapeutics Inc Azioni (GALT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Galectin Therapeutics Inc Azioni (GALT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| LEWIS JOEL | President and CEO |
Jan 02 '26 |
Option Exercise |
0.00 |
84,000 |
0 |
916,592 |
| LEWIS JOEL | President and CEO |
Jan 06 '26 |
Sale |
3.58 |
37,698 |
134,853 |
832,592 |
| LEWIS JOEL | President and CEO |
Jan 05 '26 |
Sale |
3.91 |
27,731 |
108,342 |
870,290 |
| LEWIS JOEL | President and CEO |
Jan 02 '26 |
Sale |
4.20 |
18,571 |
77,939 |
898,021 |
| CALLICUTT JACK W | Chief Financial Officer |
Jan 02 '26 |
Option Exercise |
0.00 |
60,000 |
0 |
67,614 |
| CALLICUTT JACK W | Chief Financial Officer |
Jan 05 '26 |
Sale |
3.90 |
25,732 |
100,298 |
27,968 |
| CALLICUTT JACK W | Chief Financial Officer |
Jan 06 '26 |
Sale |
3.67 |
20,354 |
74,695 |
7,614 |
| CALLICUTT JACK W | Chief Financial Officer |
Jan 02 '26 |
Sale |
4.20 |
13,914 |
58,394 |
53,700 |
| Jamil Khurram | Chief Medical Officer |
Jan 02 '26 |
Option Exercise |
0.00 |
60,000 |
0 |
60,000 |
| Jamil Khurram | Chief Medical Officer |
Jan 05 '26 |
Sale |
3.90 |
25,499 |
99,408 |
21,446 |
5.06%
1.20%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):